Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Margery A ConnellyJonathan Velez RiveraJohn R GuytonMohammad Shadab SiddiquiArun J Sanyal

Published in: Alimentary pharmacology & therapeutics (2020)

NASH is a multi-system disease with a disproportionate CVD burden. Current and future drugs for NASH have had variable impact on the atherogenic risk profile. Potential co-administration of a statin may help mitigate the negative impact of some of these therapies on lipid and lipoprotein levels.

Keyphrases

low density lipoprotein
cardiovascular disease
coronary artery disease
liver injury
type diabetes
current status
fatty acid
drug induced
risk assessment
human health
liver fibrosis